Institutional Career Development Core
机构职业发展核心
基本信息
- 批准号:10595040
- 负责人:
- 金额:$ 122.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-06-01 至 2027-02-28
- 项目状态:未结题
- 来源:
- 关键词:AlaskaAwardBehavioral SciencesChildClinicalClinical ResearchClinical SciencesCollaborationsCommunitiesCompetenceComplexDisciplineDiseaseDoctor of PhilosophyEducational CurriculumEnvironmentEthnic OriginFacultyFred Hutchinson Cancer Research CenterFundingGoalsHealthHumanIdahoInstitutionLeadMentorsMentorshipMontanaPositioning AttributePreventive measureProgram DevelopmentPublicationsRaceResearchResearch PersonnelRural HealthScientistSocial SciencesTalentsTimeTrainingTranslational ResearchUnderserved PopulationUnited States National Institutes of HealthUniversitiesWagesWashingtonWorkWyomingcareercareer developmentcohortcollaborative environmentdisabilityearly-career facultyexperienceimprovedinnovationinvestigator trainingmultidisciplinarynext generationnoveloutreachpeerprogramsrecruitrural arearural underservedsocialsocial disparitiestranslational health sciencetranslational scientist
项目摘要
Contact PD/PI: Disis, Mary L. Inst-Career-Dev-001 (378)
Given the complex challenges of developing preventative measures and novel treatments for disease and
improving health, we see an imperative to train the next generation of translational researchers in an
interdisciplinary environment. The Institute of Translational Health Sciences (ITHS)—a partnership between the
University of Washington, Seattle Children's, and Fred Hutchinson Cancer Research Center—is an incredibly
rich environment for clinical and translational research and attracts PhD, MD and other clinically trained
investigators. The reach of ITHS extends beyond its hub in Seattle across Washington, Wyoming, Alaska,
Montana, and Idaho (WWAMI), providing distinct opportunities, particularly in the areas of rural health and
underserved populations, through clinical research networks and collaborating universities. Since 2007, the ITHS
KL2 Multidisciplinary Career Development Program has cultivated a group of talented junior faculty from a wide
variety of disciplines. The primary goal of the 3-year program is to prepare a diverse group of early career faculty
to lead interdisciplinary teams conducting translational research that will ultimately improve human health. ITHS
provides salary and research funds, protected time, and mentorship to 9 scholars each year. The 62 scholars
trained to date produced 458 publications while in the program and have been awarded more than $73M in NIH
funding. ITHS now proposes to enhance the existing KL2 program through two new major aims to:
1. Create a larger, more inclusive cohort to promote scholar engagement through the addition of an
institutionally supported KL2 seminar fellows program. We will maintain 13-15 seminar fellows per year,
early career investigators who participate fully in the KL2 curriculum for up to 2 years but are supported by
other funds. The larger cohort will enrich the KL2 experience for funded scholars by providing more
opportunities for peer engagement and adding more diverse research perspectives, as well as those from
different cultural and social backgrounds, which have a positive impact on innovation.
2. Increase the diversity of the KL2 cohort to support more scientists from underrepresented
backgrounds on the basis of race/ethnicity, disability, and social disadvantage, and from regional
research organizations. We will expand outreach, purposeful recruitment, and pre-application support to
draw more investigators from outside the 3 Seattle-based partners and investigators from groups identified
by NIH as underrepresented in biomedical, clinical, behavioral, and social sciences. Centering this as a major
aim will help us create a more diverse translational research workforce.
KL2 scholars and seminar fellows will be rigorously trained using a curriculum grounded in translational science
core competencies in a unique interdisciplinary environment. Scholars benefit from guidance of their scientific
mentors and KL2 Program Directors. Graduates will be positioned to lead effective research teams that work
across disciplinary boundaries, making a positive impact on human health, and reaching a range of communities.
联系PD/PI:Disis,玛丽L.(378)第一次见面
鉴于开发疾病预防措施和新疗法的复杂挑战,
为了改善健康状况,我们认为有必要培养下一代的翻译研究人员,
跨学科的环境。转化健康科学研究所(CIMIS)-与
华盛顿大学、西雅图儿童和弗雷德哈钦森癌症研究中心是一个令人难以置信的
丰富的临床和转化研究环境,吸引了博士,医学博士和其他临床培训
investigators.美国航空航天局的业务范围超出了其在西雅图的枢纽,横跨华盛顿、怀俄明州、阿拉斯加,
蒙大拿州和爱达荷州(WWAMI)提供了独特的机会,特别是在农村卫生和
通过临床研究网络和合作大学,为得不到充分服务的人群提供服务。自2007年以来,
KL 2多学科职业发展计划培养了一批来自世界各地的优秀青年教师。
各种学科。3年计划的主要目标是准备一个多元化的早期职业教师群体
领导跨学科团队进行转化研究,最终改善人类健康。公司简介
每年为9名学者提供工资和研究基金、受保护的时间和指导。62名学者
到目前为止,在该项目中,经过培训的我发表了458篇论文,并获得了NIH超过7300万美元的奖励
经费KLS现在建议通过两个新的主要目标来加强现有的KL 2计划:
1.创建一个更大,更具包容性的队列,以促进学者参与,通过增加一个
KL 2研讨会研究员计划。我们将保持每年13-15名研讨会研究员,
早期职业调查员,他们完全参与KL 2课程长达2年,但得到以下支持:
其他基金。更大的队列将丰富KL 2的经验,为资助学者提供更多
同行参与的机会,增加更多样化的研究视角,以及来自
不同的文化和社会背景,对创新有积极的影响。
2.增加KL 2队列的多样性,以支持更多来自代表性不足的科学家
基于种族/族裔、残疾和社会不利地位的背景,以及来自区域
研究组织。我们将扩大外展,有目的的招聘和申请前的支持,
从3个总部设在西雅图的合作伙伴以外的机构和确定的团体中吸引更多的调查人员
在生物医学,临床,行为和社会科学中代表性不足。把它作为一个主要的
aim将帮助我们建立更多样化的翻译研究队伍。
KL 2学者和研讨会研究员将使用基于翻译科学的课程进行严格的培训
独特的跨学科环境中的核心竞争力。学者受益于他们的科学指导
导师和KL 2项目总监。毕业生将被定位为领导有效的研究团队,
跨越学科界限,对人类健康产生积极影响,并影响到一系列社区。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John K. Amory其他文献
Relevance of Human Aldoketoreductases and Microbial emβ/em-Glucuronidases in Testosterone Disposition
人类醛酮还原酶和微生物β-葡萄糖醛酸苷酶在睾酮处置中的相关性
- DOI:
10.1124/dmd.122.000975 - 发表时间:
2023-04-01 - 期刊:
- 影响因子:4.000
- 作者:
Abdul Basit;John K. Amory;Vijaya Saradhi Mettu;Cindy Yanfei Li;Scott Heyward;Parth B. Jariwala;Matthew R. Redinbo;Bhagwat Prasad - 通讯作者:
Bhagwat Prasad
Male hormonal contraceptive passes efficacy test in China
男性荷尔蒙避孕药在中国通过功效测试
- DOI:
10.1038/nrendo.2009.110 - 发表时间:
2009-07-01 - 期刊:
- 影响因子:40.000
- 作者:
John K. Amory - 通讯作者:
John K. Amory
Use of at-home sperm concentration testing in a male hormonal contraceptive efficacy clinical trial
在家中进行精子浓度检测在男性激素避孕有效性临床试验中的应用
- DOI:
10.1016/j.fertnstert.2024.10.004 - 发表时间:
2025-03-01 - 期刊:
- 影响因子:7.000
- 作者:
Christina Wang;Yanhe Lue;Ronald S. Swerdloff;Dayton Morris;Youngju Pak;Brian T. Nguyen;Peter Y. Liu;Mitchell D. Creinin;Prasanth Surampudi;David Turok;Kenneth I. Aston;Richard Anderson;John Reynolds-Wright;Stephanie T. Page;John K. Amory;Clint Dart;Jeffrey M. Kroopnick;Min S. Lee;Regine Sitruk Ware;Diana L. Blithe - 通讯作者:
Diana L. Blithe
Open-Channel Droplet Microfluidic Platform for Passive Generation of Human Sperm Microdroplets
用于被动生成人类精子微滴的开放通道液滴微流体平台
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:0
- 作者:
Tristan M. Nicholson;Jodie C. Tokihiro;Wan;J. Khor;Ulri N. Lee;Erwin Berthier;John K. Amory;Thomas J. Walsh;Charles H. Muller;A. Theberge - 通讯作者:
A. Theberge
ISOTRETINOIN IMPROVES <em>DE NOVO</em> SPERM PRODUCTION IN NONOBSTRUCTIVE AZOOSPERMIC AND CRYPTOZOOSPERMIC MEN
- DOI:
10.1016/j.fertnstert.2024.07.301 - 发表时间:
2024-10-01 - 期刊:
- 影响因子:
- 作者:
Ms. Molly Jessup;John K. Amory;Paul J. Turek - 通讯作者:
Paul J. Turek
John K. Amory的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John K. Amory', 18)}}的其他基金
ALDH1A1/A2 Inhibitors for Male Contraception
用于男性避孕的 ALDH1A1/A2 抑制剂
- 批准号:
10430041 - 财政年份:2019
- 资助金额:
$ 122.65万 - 项目类别:
ALDH1A1/A2 Inhibitors for Male Contraception
用于男性避孕的 ALDH1A1/A2 抑制剂
- 批准号:
10172963 - 财政年份:2019
- 资助金额:
$ 122.65万 - 项目类别:
ALDH1A1/A2 Inhibitors for Male Contraception
用于男性避孕的 ALDH1A1/A2 抑制剂
- 批准号:
10651653 - 财政年份:2019
- 资助金额:
$ 122.65万 - 项目类别:
ALDH1A1/A2 Inhibitors for Male Contraception
用于男性避孕的 ALDH1A1/A2 抑制剂
- 批准号:
10020794 - 财政年份:2019
- 资助金额:
$ 122.65万 - 项目类别:
相似海外基金
Open Access Block Award 2024 - Durham University
2024 年开放访问区块奖 - 杜伦大学
- 批准号:
EP/Z531480/1 - 财政年份:2024
- 资助金额:
$ 122.65万 - 项目类别:
Research Grant
Open Access Block Award 2024 - Goldsmiths College
2024 年开放获取区块奖 - 金史密斯学院
- 批准号:
EP/Z531509/1 - 财政年份:2024
- 资助金额:
$ 122.65万 - 项目类别:
Research Grant
Open Access Block Award 2024 - John Innes Centre
2024 年开放访问区块奖 - 约翰·英尼斯中心
- 批准号:
EP/Z53156X/1 - 财政年份:2024
- 资助金额:
$ 122.65万 - 项目类别:
Research Grant
Open Access Block Award 2024 - London School of Economics & Pol Sci
2024 年开放获取区块奖 - 伦敦政治经济学院
- 批准号:
EP/Z531625/1 - 财政年份:2024
- 资助金额:
$ 122.65万 - 项目类别:
Research Grant
Open Access Block Award 2024 - Oxford Brookes University
2024 年开放获取区块奖 - 牛津布鲁克斯大学
- 批准号:
EP/Z531728/1 - 财政年份:2024
- 资助金额:
$ 122.65万 - 项目类别:
Research Grant
Open Access Block Award 2024 - The Francis Crick Institute
2024 年开放获取区块奖 - 弗朗西斯·克里克研究所
- 批准号:
EP/Z531844/1 - 财政年份:2024
- 资助金额:
$ 122.65万 - 项目类别:
Research Grant
Open Access Block Award 2024 - The Natural History Museum
2024 年开放访问区块奖 - 自然历史博物馆
- 批准号:
EP/Z531856/1 - 财政年份:2024
- 资助金额:
$ 122.65万 - 项目类别:
Research Grant
Open Access Block Award 2024 - University of Brighton
2024 年开放获取区块奖 - 布莱顿大学
- 批准号:
EP/Z531935/1 - 财政年份:2024
- 资助金额:
$ 122.65万 - 项目类别:
Research Grant
Open Access Block Award 2024 - University of Bristol
2024 年开放获取区块奖 - 布里斯托大学
- 批准号:
EP/Z531947/1 - 财政年份:2024
- 资助金额:
$ 122.65万 - 项目类别:
Research Grant
Open Access Block Award 2024 - University of Bradford
2024 年开放获取区块奖 - 布拉德福德大学
- 批准号:
EP/Z531923/1 - 财政年份:2024
- 资助金额:
$ 122.65万 - 项目类别:
Research Grant














{{item.name}}会员




